Bio-Path Holdings Inc (BPTH)
Bio-Path Holdings is a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company utilizing a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Co.'s primary drug candidate, prexigebersen, which targets growth factor receptor-bound protein 2, initially started the efficacy portion of a Phase 2 clinical trial for untreated acute myeloid leukemia patients. Co.'s second drug candidate, Liposomal Bcl-2, targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. Co.'s third drug candidate, Liposomal STAT3, targets the STAT3 protein.
Company Name: |
Bio-Path Holdings Inc |
Website: |
www.biopathholdings.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding BPTH: |
1 |
Total Market Value Held by ETFs: |
$55898 |
Total Market Capitalization: |
$3.00M |
% of Market Cap. Held by ETFs: |
1.86% |
|
|
March 29, 2024 1:40 AM Eastern
Strong Buy (4.00 out of 4)
96th percentile
|
|